Teriparatide · source year
4 selected, source-linked Teriparatide records carrying a 2021 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
1 represented type.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗